Guoyu Li

Guoyu Li

Auto-generated profile, based on publicly available information

Guoyu Li

Department of Medicinal Chemistry, Pharmacology, Project Management, Drug Metabolism and Pharmacokinetics, TransThera Sciences (Nanjing), Inc., Nanjing, Jiangsu, P.R. China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Triple-negative breast cancer (TNBC) is a highly heterogeneous cancer lacking actionable targets. Using a phenotypic screen of TNBC cells, we discovered a novel multiple kinase inhibitor tinengotinib (TT-00420) that strongly inhibited Aurora A/B, FGFR1/2/3, VEGFRs, JAK1/2, and CSF1R in biochemical assays. Exposure to tinengotinib specifically inhibited proliferation across all subtypes of TNBC in vitro and in vivo, while leaving luminal breast cancer cells intact. Incubation of HCC1806 with tinengotinib led to dose-dependent downregulation of genes essential for TNBC cell growth and proliferation. Studies revealed that the potential mechanism of action of tinengotinib involved, predominantly, inhibition of Aurora A or B kinase activity, while inhibition of other pathways contributed to suppression of potency and activity. In vitro treatment of TNBC cell lines or in vivo administration in a syngeneic model with tinengotinib resulted in up-regulation of CXCL10 and 11 or diminished tumor-associated macrophage (TAM) infiltration. Tinengotinib represents a novel combinatorial inhibitory mechanism to treat TNBC. The phase I trial of tinengotinib was completed (ClinicalTrials.gov identifier: NCT03654547).

3 April 2023
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
As shown in Figure 2, Image J was applied for semi-quantification for each protein level as indicated.

27 November 2025
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Tinengotinib effectively blocks Aurora kinase signaling pathway.

27 November 2025
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Tinengotinib highly inhibits TNBC cell by a panel of specific mechanisms.

27 November 2025
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Tinengotinib possesses robust immunomodulatory activity.

27 November 2025
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Tinengotinib is well tolerated through the in vivo studies and body weight curves are shown.